Syneos Health, Inc.

Syneos Health, Inc. is a biopharmaceutical solutions organization based in the US, specializing in comprehensive services that cover the entire spectrum from clinical development to commercial delivery for the pharmaceutical sector. Syneos Health, Inc. provides integrated biopharmaceutical solutions focused on delivering direct services to mid-sized and large biopharmaceutical companies.

Founded in 2017 in Morrisville, US, the company has completed 2 deals, with the most recent being a Public to Private, Secondary Buyout transaction on May 9, 2023. This involved Elliott Management, Patient Square Capital, and Veritas Capital acquiring a 90% majority stake for USD 4. 46 bn, totaling USD 7. 1 bn including outstanding debt.

Founders include Kira Cook, Laura Silvius, Mohammad Hajikandi, Nick Pearson, Pathan Khan, Paul Robinson, Stephanie Nelson, Subhan Khan, Tiemo Hunger, and Valeri Manziuk, with Alistair Macdonald serving as CEO. Syneos Health operates as a fully integrated biopharmaceutical solutions organization, providing a comprehensive array of services that span clinical development, regulatory affairs, commercial delivery, and post-launch marketing. The company utilizes AI and technology-enabled insights to enhance performance and mitigate risks in drug development, focusing particularly on oncology and hematology. Syneos Health serves clients globally, with a notable presence in North America, Europe, and Asia-Pacific regions, delivering tailored solutions aimed at meeting the specific needs of pharmaceutical firms.

In 2022, Syneos Health generated a revenue of USD 5,393. 08 mn and an EBITDA of USD 650. 37 mn. The company generates revenue through B2B transactions with pharmaceutical and biotechnology clients, leveraging its extensive suite of biopharmaceutical solutions and customizing service contracts according to client needs.

In May 2023, following the acquisition by Elliott Associates, Patient Square Capital, and Veritas Capital, Syneos Health plans to utilize its new funding to bolster its core capabilities and enhance the distribution of its medical innovations. The company aims to expand into new markets and geographic regions, although specific details on targeted markets and timelines for expansion have not been disclosed. This investment is expected to support upcoming product launches and further strengthen Syneos Health's position in the biopharmaceutical landscape.